Abstract:Background: Converging evidence suggests that markers of Alzheimer's disease (AD) pathology in cognitively unimpaired older individuals are associated with high risk of cognitive decline and progression to functional impairment. The Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) and Longitudinal Evaluation of Amyloid and Neurodegeneration Risk (LEARN) Studies enrolled a large cohort of cognitively normal older individuals across a range of baseline amyloid PET levels. Recent advances in AD blood-based biomarkers further enable the comparison of baseline markers in the prediction of longitudinal clinical outcomes. Objectives: We sought to evaluate whether biomarker indicators of higher levels of AD pathology at baseline predicted greater cognitive and functional decline, and to compare the relative predictive power of amyloid PET imaging, tau PET imaging, and a plasma P-tau217 assay. Design: All participants underwent baseline amyloid PET scan, plasma P-tau217; longitudinal cognitive testing with the Primary Alzheimer Cognitive Composite (PACC) every 6 months; and annual functional assessments with the clinical dementia rating (CDR), cognitive functional index (CFI), and activities of daily living (ADL) scales. Baseline tau PET scans were obtained in a subset of participants. Participants with elevated amyloid (Aβ+) on screening PET who met inclusion/exclusion criteria were randomized to receive placebo or solanezumab in a double-blind phase of the A4 Study over 240+ weeks. Participants who did not have elevated amyloid (Aβ-) but were otherwise eligible for the A4 Study were referred to the companion observational LEARN Study with the same outcome assessments over 240+ weeks. Setting: The A4 and LEARN Studies were conducted at 67 clinical trial sites in the United States, Canada, Japan and Australia. Participants: Older participants (ages 65-85) who were cognitively unimpaired at baseline (CDR-GS=0, MMSE 25-30 with educational adjustment, and Logical Memory scores within the normal range LMIIa 6-18) were eligible to continue in screening. Aβ+ participants were randomized to either placebo (n=583) or solanezumab (n=564) in the A4 Study. A subset of Aβ+ underwent tau PET imaging in A4 (n=350). Aβ- were enrolled into the LEARN Study (n=553). Measurements: Baseline 18-F Florbetapir amyloid PET, 18-F Flortaucipir tau PET in a subset and plasma P-tau217 with an electrochemiluminescence (ECL) immunoassay were evaluated as predictors of cognitive (PACC), and functional (CDR, CFI and ADL) change. Models were evaluated to explore the impact of baseline tertiles of amyloid PET and tertiles of plasma P-tau217 on cognitive and functional outcomes in the A4 Study compared to LEARN. Multivariable models were used to evaluate the unique and common variance explained in longitudinal outcomes based on baseline predictors, including effects for age, gender, education, race/ethnic group, APOEε4 carrier status, baseline PACC performance and treatment assignment in A4 participants (solanezumab vs placebo). Results: Higher baseline amyloid PET CL and P-tau217 levels were associated with faster rates of PACC decline, and increased likelihood of progression to functional impairment (CDR 0.5 or higher on two consecutive measurements), both across LEARN Aβ- and A4 Aβ+ (solanezumab and placebo arms). In analyses considering all baseline predictor variables, P-tau217 was the strongest predictor of PACC decline. Among participants in the highest tertiles of amyloid PET or P-tau217, >50% progressed to CDR 0.5 or greater. In the tau PET substudy, neocortical tau was the strongest predictor of PACC decline, but plasma P-tau217 contributed additional independent predictive variance in commonality variance models. Conclusions: In a large cohort of cognitively unimpaired individuals enrolled in a Phase 3 clinical trial and companion observational study, these findings confirm that higher baseline levels of amyloid and tau markers are associated with increased rates of cognitive decline and progression to functional impairment. Interestingly, plasma P-tau217 was the best predictor of decline in the overall sample, superior to baseline amyloid PET. Neocortical tau was the strongest predictor of cognitive decline in the subgroup with tau PET, suggesting that tau deposition is most closely linked to clinical decline. These findings indicate that biomarkers of AD pathology are useful to predict decline in an older asymptomatic population and may prove valuable in the selection of individuals for disease-modifying treatments.

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST

Impact of Different PET Image Quantification Methods, Regions-of-interest and Risk Factors on the Power to Detect a Slowing in Beta-Amyloid Deposition in Presymptomatic Alzheimer's Disease Trials

Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.

P2‐071: comparing cerebral white matter, cerebellar, and pontine reference regions to characterize florbetapir pet measurements of amyloid‐β burden in psen1 e280a mutation carriers and noncarriers from the colombian autosomal dominant alzheimer's disease kindred

IC‐P‐010: COMPARING CEREBRAL WHITE MATTER, CEREBELLAR, AND PONTINE REFERENCE REGIONS TO CHARACTERIZE FLORBETAPIR PET MEASUREMENTS OF AMYLOID‐β BURDEN IN PSEN1 E280A MUTATION CARRIERS AND NONCARRIERS FROM THE COLOMBIAN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE KINDRED

Impact of Reference Region on Longitudinal Florbetapir PET SUVR Changes from the API ADAD Colombia Trial

Closer Correlations Between Florbetapir PET Measurements of Amyloid Plaque Burden Using a Cerebral White Matter Reference Region and Alzheimer’s Disease‐related Hypometabolism

Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies

Parametric Estimation of Reference Signal Intensity in the Quantification of Amyloid-Beta Deposition: an 18F-AV-45 Study.

Using Positron Emission Tomography And Florbetapir F 18 To Image Cortical Amyloid In Patients With Mild Cognitive Impairment Or Dementia Due To Alzheimer Disease

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease

Florbetapir PET Measurements of Amyloid Plaque Deposition Are More Closely Correlated with Cross‐Sectional and Longitudinal Cognitive and Clinical Measurements Using a White Matter Reference Region of Interest

Changes of plasma Aβ and t-tau along with 18F-florbetapir PET in a cohort of cognitive decline

Quantitative Imaging Apoe4 Effects On Brain Tau Deposition And Glucose Metabolism In Mild Cognitive Impairment Patients With [F-18]Av1451 And [F-18]Fdg Pet

Amyloid Imaging in Therapeutic Trials: the Quest for the Optimal Reference Region

O3‐02‐02: AMYLOID PET, TAU PET, AND MRI MEASUREMENTS IN COGNITIVELY UNIMPAIRED PERSONS WITH TWO, ONE, AND NO COPIES OF THE APOE4 ALLELE

Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies

Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer's disease preclinical phase evaluated by dual-phase 18F-florbetaben positron emission tomography

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease